Rituximab-induced diffuse ischemic colitis: A case report
DOI:
https://doi.org/10.30574/gscbps.2021.14.2.0036Keywords:
Rituximab, Pancolitis, Colon biopsy, Mucosal ischemia, Adverse reactionAbstract
In the present manuscript a case of a 61 years old man with a form of unclear colitis is reported. The patient presented to our hospital with history of prolonged diarrhea and consequent profound dehydration after treatment with an immunotherapeutic cycle with Rituximab for a B cell lymphoma. An endoscopic pan-colonic examination was performed and some intestinal randomized biopsies were done as to confirm the clinic hypothesis of a colitis, as to define its etiopathogenesis. Histopathological picture of the colon biopsy fragments suggested a diffuse colitis with ischemic aspects. Herein the involvement of rituximab in determining pancolitis is discussed.
Metrics
References
Ronald Hoffman MD, Bruce Furie MD, Edward J, Benz Jr MD, Philip McGlave MD, Leslie E. Silberstein, MD e Sanford J. Shattil, MD, “Hematology, 5th Edition - Basic Principles and Practice“, ElsevierMasson. 2008.
Liu Y, Barta SK. Diffuse large B-celllymphoma: 2019 update on diagnosis, riskstratification, and treatment American Journal of Hematology. May 2019; 94(5): 604-616.
Abramson JS. Hitting back atlymphoma: How domoderndiagnosticsidentify high-risk diffuse large B-celllymphomasubsets and alter treatment? Cancer. Sep 2019; 125(18): 3111-3120.
Chavex JC, Locke FL. CAR T celltherapy for B-celllymphomas” Best practice and Research, ClinicalHaematology. June 2018;31(2): 135-146.
Sukswai N, Lyapichev K, Khoury JD, Medeiros LJ. Diffuse large B-celllymphomavariants: an update, Pathology. Nov 2019; 52(1): 53-67.
Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committeecovented to discuss the evaluation and staging of patients with Hodgkin’sdisease: Cotswolds meeting J. Clin. Oncol. Nov 1989; 7(11): 1630-1636.
Li S, Young KH, Medeiros LJ. Diffuse large B-celllymphoma” Pathology. Jan 2018; 50(1): 74-87.
Cabanillas F, Shah B. Advances in Diagnosis and Management of Diffuse Large B-cellLymphoma,Clinical Lymphoma, Myeloma&Leukemia. Dec 2017; 17(12): 783–796.
Gisselbrecht C, Van DenNeste E. How i managespatients with relapsed/refractory diffuse large B celllymphoma”, British of Journal Haematology. Sep 2018; 182(5): 633-643.
Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, Lowe DC, Sleeman MA, Davis DM. Scientistdiscoverwhy a specificcancerdrugis so effective, Blood. 2013; 121(23): 4694-4702.
Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, Lowe DC, Sleeman MA, Davis DM. Rituximabcauses a polarization of B cellsthataugmentsitstherapeuticfunction in NK-cell-mediatedantibody-dependentcellularcytotoxicity, Blood. 2013; 121(23): 4694-4702.
Shaw T. B celltherapy for rheumatoidarthritis: The rituximab (anti-CD20) experience Ann. Of the RheumaticDiseases. 2003; 62(90002): 55ii-59.
Edwards J, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D, Stevens R, Shaw T. Efficacy of B-cell-targetedtherapy with rituximab in patients with rheumatoidarthritis N. Engl. J. Med. 2004; 350(25): 2572-2581.
Molloy, Eamonn S, Calabrese, Leonard H. Progressive multifocalleukoencephalopathyassociated with immunosuppressivetherapy in rheumaticdiseases: Evolvingrole of biologictherapies. Arthritis&Rheumatism, 2012, 64(9): 3043–3051.
Burton C, Kaczmarski R, Jan-Mohamed R. Interstitialpneumonitisrelated to rituximabtherapy. N Engl J Med. 2003; 348(26): 2690–1.
Roche Canada, Reports of BowelObstruction and Perforation with RITUXAN (rituximab). 10 Nov 2006.
Hugh James Freeman. Colitisassociated with biological agents”, World Journal of Gastroenterology. 28 April 2012; 18(16): 1871-1874.
Seth LMD, Seymour K, MD, James MC. MD PhD. FulminantColitisfollowingRituximabTherapy, Gastroenterology and Hepatology. Jan 2016; 12(1).
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
